Immune regulation of procalcitonin: Abiomarker and mediator of infection

Inflammation Research

Volumn 61, Issue 5, 2012, Pages 401-409

  Matwiyoff, G N ^a   Prahl, J D ^a   Miller, R J ^a   Carmichael, J J ^a   Amundson, D E ^b   Seda, G ^a   Daheshia, M ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

Biomarker; Infection; Inflammation; Procalcitonin; Regulation

Indexed keywords

C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

CALC 1 GENE; CYTOKINE RELEASE; ESCHERICHIA COLI INFECTION; GENE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; INFLAMMATION; MORTALITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SEPSIS; SEPTIC SHOCK; TRANSCRIPTION REGULATION;

ANIMALS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; HUMANS; IMMUNOMODULATION; PROTEIN PRECURSORS;

EID: 84863113328     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0439-5     Document Type: Review

References (79)

1. AssicotM, Gendrel D, Carsin H, Raymond J, Guilbaud J, BohuonC. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515-8.
2. Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, Ricchetti SM. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res. 2010;59(8):581-6.
3. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206-17.
4. Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. Intensive Care Med. 2000;26(SUPPL. 2):178-81.
5. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011;2011:594-645.
6. Lai CC, Tan CK, Chen SY, Wang CY, Liu WL, Hou CC, Hsueh PR. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512-5.
7. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112(5):1054-60.
8. Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52(2):276-81.
9. Wunder C, Eichelbron̈ner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res. 2004;53(4):158-63.
10. Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996;312(1):12-8.
11. Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26(3):331.e1-7.
12. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, et al. Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-66.
13. Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010;159(2):253-64.
14. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. 1999;37(8):789-97.
15. Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990;28(2):109-74.
16. Peleg S, Abruzzese RV, Cote GJ, Gagel RF. Transcription of the human calcitonin gene is mediated by a C cell-specific enhancer containing E-box-like elements. Mol Endocrinol. 1990;4(11): 1750-7.
17. Peleg S. Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res. 1993;21(23):5360-5.
18. Monla YT, Peleg S, Gagel RF, Monia YT. Cell type-specific regulation of transcription by cyclic adenosine 30, 50-monophosphate- responsive elements within the calcitonin promoter. Mol Endocrinol. 1995;9(7):784-93.
19. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45(9):552-60.
20. Bolko P, Manuszewska-Jopek E, Michałek K, Waśko R, Jaskuła M, Sowiński J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz). 2003;51(6):415-9.
21. Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999;25(9):1031.
22. Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290-5.
23. Domenech VS, Nylen ES, White JC, Snider RH, Becker KL, Landmann R, Müller B. Calcitonin gene-related peptide expression in sepsis: postulation of microbial infection-specific response elements within the calcitonin I gene promoter. J Investig Med. 2001;49(6):514-21.
24. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001; 86(1):396-404.
25. Giunti M, Peli A, Battilani M, Zacchini S, Militerno G, Otto CM. Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome. J Vet Emerg Crit Care (San Antonio). 2010;20(5):523-7.
26. Meisner M, Müller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19(2):187-90.
27. Silomon M, Bach F, Ecker D, Graeter T, Grundmann U, Larsen R. Procalcitonin after extracorporeal circulation. Synthesis in the hepatosplanchnic region. Anaesthesist. 1999;48(6):395-8.
28. Kretzschmar M, Krüger A, Schirrmeister W. Procalcitonin following elective partial liver resection-origin from the liver? Acta Anaesthesiol Scand. 2001;45(9):1162-7.
29. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134(1):49-55.
30. Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61(2):180-6.
31. Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G. Canine procalcitonin messenger RNA expression. J Vet Diagn Invest. 2008;20(5):629-33.
32. Oberhoffer M, Vogelsang H, Jäger L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999; 14(1):29-33.
33. Balog A, Ocsovszki I, Mándi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett. 2002;84(3):199-203.
34. Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27(1):34-5.
35. Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578-84.
36. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin generelated peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32(8):1715-21.
37. Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6-7):471-8.
38. Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59(5):339-47.
39. Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2010. [Epub ahead of print].
40. Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):75-85.
41. Axer H, Wohlfarth M, Meisner M, Finn S, Ragoschke-Schumm A, Mentzel HJ, et al. Procalcitonin as a marker for severe sepsis in an immunosuppressed patient. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005;40(2):97-102.
42. Al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection. 1996;24(6):434-6.
43. Picariello C, Lazzeri C, Valente S, Chiostri M, Attanà P, Gensini GF. Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card Care. 2010;12(3):96-101.
44. Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab. 2008;295(3):686-91.
45. Preas HL 2nd, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373-6.
46. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605-8.
47. Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis. 2008;26(8):38.
48. Kim KE, Han JY. Evaluation of the clinical performance of an automated procalcitonin assay for the quantitative detection of bloodstream infection. Korean J Lab Med. 2010;30(2): 153-9.
49. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539-44.
50. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28(2): 458-61.
51. Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000;28(4):1040-6.
52. Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock. 2000;14(1):73-8.
53. Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, Falagas ME. Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest. 2008;38(4):276-9.
54. Chakrabartty S, Apong S. Procalcitonin estimation in Kawasaki disease. Indian Pediatr. 2009;46(7):648.
55. Barati M, Alinejad F, Bahar MA, Tabrisi MS, Shamshiri AR, Bodouhi NO, Karimi H. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008;34(6):770-4.
56. Latour-Pérez J, Alcalá-López A, García- García MA, Sánchez- Hernández JF, Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010;43(9):720-4.
57. Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth. 2006;97(4):503-8.
58. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396-402.
59. Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC. Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care. 1999;3(1): 11-6.
60. Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26(6):1001-6.
61. Wagner KE, Martinez JM, Vath SD, Snider RH, Nylén ES, Becker KL, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med. 2002;30(10):2313-21.
62. Tavares E, Miñano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond). 2010;119(12):519-34.
63. Martinez JM, Wagner KE, Snider RH, Nylen ES, Muller B, Sarani B. Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg Infect (Larchmt). 2001;2(3):193-202. discussion 202-203.
64. Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res. 2011;60(2):203-7.
65. Wei JX, Verity A, Garle M, Mahajan R, Wilson V. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. Br J Anaesth. 2008;100(5):612-21.
66. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112-7.
67. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127-32.
68. Pincíková T, Bucová M, Slobodníková L. Influence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood against bacteria Staphylococcus aureus and Escherichia coli. Vnitr Lek. 2005;51(12):1365-70.
69. Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPSinduced tnf production by human circulating blood cells. Cytokine. 2000;12(6):762-4.
70. Bucova M, Zahorec R, Buc M. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. Cent Eur J Immunol. 2006;31:87-93.
71. Hoffmann G, Schobersberger W. Anti-inflammatory procalcitonin (PTC) in a human whole blood model septic shock. Cytokine. 2000;12(6):762-4.
72. Hoffmann G, Totzke G, Seibel M, Smolny M, Wiedermann FJ, Schobersberger W. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med. 2001;29(1):112-6.
73. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002;30(9):2091-5.
74. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011. [Epub ahead of print].
75. Jereb M, Lunaček NK, Kotar T, Saksida A, Petrovec M, Avšič- Županc T. Procalcitonin in hantavirus infections. Scand J Clin Lab Invest. 2011;71(4):287-91.
76. Christ-Crain M, Müller B. Procalcitonin and pneumonia: is it a useful marker? Curr Infect Dis Rep. 2007;9(3):233-40.
77. Becker KL, Bivins LE, Radfar RH, Snider RH, Moore CF, Silva OL. Study of calcitonin heterogeneity using a radioreceptor assay. Horm Metab Res. 1978;10(5):457-8.
78. Jullienne A, Raulais D, Calmettes C, Moukhtar MS, Milhaud G. Heterogeneity of immunoreactive calcitonin in normal human thyroid. Horm Metab Res. 1978;10(5):456-7.
79. Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH Jr, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36(5):1637-40.